DASHENLIN PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.12 CNY | -2.60% |
|
-7.48% | -47.31% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 27,171 | 51,603 | 33,307 | 37,585 | 28,359 | 14,942 | - | - |
| Enterprise Value (EV) 1 | 25,784 | 49,252 | 32,838 | 36,233 | 27,369 | 13,426 | 12,856 | 12,174 |
| P/E ratio | 41.5 x | 48.4 x | 42.1 x | 36.3 x | 24.2 x | 10.6 x | 8.8 x | 7.28 x |
| Yield | 1.15% | 1.02% | 1.19% | 1.52% | 1.24% | 2.38% | 3.39% | 3.46% |
| Capitalization / Revenue | 2.44 x | 3.54 x | 1.99 x | 1.77 x | 1.16 x | 0.51 x | 0.42 x | 0.35 x |
| EV / Revenue | 2.31 x | 3.38 x | 1.96 x | 1.71 x | 1.12 x | 0.46 x | 0.36 x | 0.28 x |
| EV / EBITDA | 21.3 x | 27.5 x | 13.6 x | 19.2 x | 12.9 x | 4.32 x | 3.62 x | 2.83 x |
| EV / FCF | 21.2 x | 42 x | 117 x | 13.1 x | 19.7 x | 4.44 x | 4.66 x | 3.78 x |
| FCF Yield | 4.71% | 2.38% | 0.86% | 7.61% | 5.09% | 22.5% | 21.5% | 26.5% |
| Price to Book | 6.65 x | 9.93 x | 6.3 x | 6.24 x | 4.16 x | 1.89 x | 1.63 x | 1.38 x |
| Nbr of stocks (in thousands) | 1,078,303 | 1,138,102 | 1,138,968 | 1,138,947 | 1,138,902 | 1,138,848 | - | - |
| Reference price 2 | 25.20 | 45.34 | 29.24 | 33.00 | 24.90 | 13.12 | 13.12 | 13.12 |
| Announcement Date | 4/28/20 | 4/19/21 | 4/27/22 | 4/27/23 | 4/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 11,141 | 14,583 | 16,759 | 21,248 | 24,531 | 29,398 | 35,643 | 42,794 |
| EBITDA 1 | 1,211 | 1,788 | 2,408 | 1,883 | 2,119 | 3,110 | 3,556 | 4,297 |
| EBIT 1 | 918.3 | 1,448 | 1,041 | 1,421 | 1,632 | 2,077 | 2,481 | 2,977 |
| Operating Margin | 8.24% | 9.93% | 6.21% | 6.69% | 6.65% | 7.07% | 6.96% | 6.96% |
| Earnings before Tax (EBT) 1 | 919.5 | 1,446 | 1,044 | 1,415 | 1,628 | 1,956 | 2,369 | 2,862 |
| Net income 1 | 702.7 | 1,062 | 791.2 | 1,036 | 1,166 | 1,404 | 1,697 | 2,050 |
| Net margin | 6.31% | 7.28% | 4.72% | 4.87% | 4.76% | 4.77% | 4.76% | 4.79% |
| EPS 2 | 0.6076 | 0.9375 | 0.6944 | 0.9083 | 1.030 | 1.234 | 1.491 | 1.802 |
| Free Cash Flow 1 | 1,214 | 1,174 | 281.7 | 2,759 | 1,392 | 3,023 | 2,759 | 3,222 |
| FCF margin | 10.9% | 8.05% | 1.68% | 12.99% | 5.67% | 10.28% | 7.74% | 7.53% |
| FCF Conversion (EBITDA) | 100.27% | 65.67% | 11.7% | 146.56% | 65.68% | 97.21% | 77.58% | 74.99% |
| FCF Conversion (Net income) | 172.76% | 110.52% | 35.6% | 266.4% | 119.32% | 215.38% | 162.53% | 157.17% |
| Dividend per Share 2 | 0.2894 | 0.4630 | 0.3472 | 0.5000 | 0.3100 | 0.3126 | 0.4450 | 0.4540 |
| Announcement Date | 4/28/20 | 4/19/21 | 4/27/22 | 4/27/23 | 4/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4,404 | 4,677 | 5,044 | 5,097 | 6,430 | 5,947 | 6,045 | 5,731 | 6,808 | 6,752 | 7,220 | 7,275 | 8,317 | 8,351 | 9,135 |
| EBITDA 1 | - | 614 | 498.6 | 426.9 | - | - | - | - | - | 570.9 | 952.7 | 952.7 | 855.6 | 1,000 | 1,051 |
| EBIT 1 | -41.44 | 492.4 | 438.9 | 291.9 | 197.6 | 684.1 | 576.8 | 371.6 | 27.43 | 570.9 | 617.7 | 503.6 | 338.5 | 578.8 | 632.9 |
| Operating Margin | -0.94% | 10.53% | 8.7% | 5.73% | 3.07% | 11.5% | 9.54% | 6.48% | 0.4% | 8.45% | 8.56% | 6.92% | 4.07% | 6.93% | 6.93% |
| Earnings before Tax (EBT) 1 | -34.41 | 493.8 | 443.4 | 288.6 | 189 | 679.4 | 547.3 | 363.7 | 37.46 | 572 | 498 | 498 | 424 | 563.5 | 612.5 |
| Net income 1 | -27.1 | 384.2 | 330 | 209.1 | 112.5 | 496.8 | 420.7 | 256.9 | -7.86 | 398.5 | 356.9 | 356.9 | 315.3 | 403.8 | 438.9 |
| Net margin | -0.62% | 8.22% | 6.54% | 4.1% | 1.75% | 8.35% | 6.96% | 4.48% | -0.12% | 5.9% | 4.94% | 4.91% | 3.79% | 4.84% | 4.81% |
| EPS 2 | -0.0347 | 0.3403 | 0.2848 | 0.1833 | 0.1000 | 0.4333 | 0.3767 | 0.2200 | 0.3500 | 0.3500 | 0.3811 | 0.3311 | 0.1656 | 0.3415 | 0.3627 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | 0.3100 | - | - | - | 0.3794 |
| Announcement Date | 4/27/22 | 4/27/22 | 8/29/22 | 10/27/22 | 4/27/23 | 4/27/23 | 8/29/23 | 10/30/23 | 4/28/24 | 4/28/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 1,387 | 2,351 | 469 | 1,352 | 990 | 1,516 | 2,086 | 2,767 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 1,214 | 1,174 | 282 | 2,759 | 1,392 | 3,023 | 2,759 | 3,222 |
| ROE (net income / shareholders' equity) | 20.4% | 22.7% | 14.6% | 17.9% | 18% | 18.5% | 20% | 20% |
| ROA (Net income/ Total Assets) | 9.24% | 10.1% | 5.33% | 5.43% | 5.07% | 5.46% | 6.05% | 6.23% |
| Assets 1 | 7,605 | 10,502 | 14,834 | 19,088 | 22,989 | 25,708 | 28,066 | 32,932 |
| Book Value Per Share 2 | 3.790 | 4.560 | 4.640 | 5.290 | 5.990 | 6.930 | 8.040 | 9.520 |
| Cash Flow per Share 2 | 1.530 | 1.720 | 1.370 | 3.300 | 2.790 | 2.270 | 2.950 | 3.530 |
| Capex 1 | 494 | 780 | 1,273 | 997 | 1,782 | 1,002 | 1,178 | 1,298 |
| Capex / Sales | 4.43% | 5.35% | 7.6% | 4.69% | 7.26% | 3.41% | 3.3% | 3.03% |
| Announcement Date | 4/28/20 | 4/19/21 | 4/27/22 | 4/27/23 | 4/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
13.12
CNY
Average target price
30.54
CNY
Spread / Average Target
+132.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -47.31% | 2.06B | |
| -55.96% | 9.93B | |
| -44.37% | 9.29B | |
| -23.35% | 6.82B | |
| -2.08% | 6.45B | |
| +92.40% | 5.26B | |
| -2.63% | 4.62B | |
| +5.79% | 4.56B | |
| -31.67% | 3.81B | |
| +4.94% | 3.06B |
- Stock Market
- Equities
- 603233 Stock
- Financials DaShenLin Pharmaceutical Group Co., Ltd.
